Skip to main content

Goodpasture Syndrome clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • Imlifidase in Anti-GBM Disease

    open to eligible people ages 18 years and up

    An open-label, controlled, randomised, multi-centre Phase 3 trial evaluating renal function in patients with severe anti-GBM disease comparing imlifidase and standard of care (SoC) with SoC alone. All patients will remain in the trial for 24 months.

    at UCLA

Last updated: